Market Place
Sourcing Support
Destiny Goes Private After Failing To Find Partner For Drug
15 Jul 2024 //
FIERCE BIOTECH
Destiny ends COVID collab, Santhera returns lonodelestat
25 Apr 2024 //
FIERCE BIOTECH
Destiny Pharma & SporeGen® announce update from research collaboration
02 May 2023 //
PHARMIWEB
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
27 Feb 2023 //
ENDPTS
Destiny seals C. diff therapy`s phase 3 fate with Sebela
24 Feb 2023 //
FIERCE BIOTECH
Destiny Pharma targets growth as anti-infection treatments return to prominence
18 Nov 2022 //
PROACTIVEINVESTORS
Destiny Pharma PLC - Study gives strong support for potential of XF-73
18 Oct 2021 //
VOXMARKET
Destiny Pharma: Expansion of clinical pipeline
27 Sep 2021 //
STOCKMARKETWIRE
Destiny Pharma & US Department of Veterans Affairs enter into R&D Agreement
06 Jul 2021 //
MARKETSCREENER
XF-73 data abstract to be presented at 2021 ECCMID
10 Jun 2021 //
PRESS RELEASE
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2
06 Apr 2021 //
BUSINESSWIRE
Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel
29 Mar 2021 //
SHARESMAGAZINE
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
09 Mar 2021 //
INVESTEGATE
Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
03 Feb 2021 //
SWISSMEDIC
Destiny Pharma PLC Fundraising and Acquisition
09 Nov 2020 //
INVESTEGATE
Update on Phase 2b clinical study of lead asset XF-73
17 Sep 2020 //
PHARMIWEB
Destiny, SporeGen collaborate on COVID-19 prevention spray
07 Sep 2020 //
PHARMATIMES
Destiny Pharma’s novel antibiotic asset clears safety review
10 Aug 2020 //
PHARMATIMES
Independent expert review of data supports the potential of XF-73
05 May 2020 //
PHARMIWEB
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.